Skip to content
Colorectal Cancer Clinical Trials

Seattle, Washington

Colorectal cancer clinical trials in Seattle, WA

50 colorectal cancer studies are recruiting participants at sites in Seattle as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Seattle at a glance

  • 50 studies are recruiting at a site in Seattle.
  • By phase: Phase 1 (10), Phase 1/2 (13), Phase 2 (6), Phase 2/3 (1), Phase 3 (8), No phase (3), Observational (9). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (36), university, hospital or other (14).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Seattle

Basic details from each study's public record (the 30 most recently updated of 50). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT06324357 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Virginia Mason Medical Center
    Registry record
    NCT07488676 · updated
  3. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Fred Hutchinson Cancer Center ( Site 0076)
    Registry record
    NCT06997497 · updated
  4. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Virginia Mason Medical Center
    Registry record
    NCT07659795 · updated
  5. Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Solstice Oncology, Inc.
    Registry record
    NCT07808151 · updated
  6. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Virginia Mason Medical Center
    Registry record
    NCT07020221 · updated
  7. Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Swedish Medical Center-Ballard Campus · Swedish Medical Center-Cherry Hill · Swedish Medical Center-First Hill
    Registry record
    NCT07018869 · updated
  8. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    FHCC at Northwest Hospital · Fred Hutchinson Cancer Center · Swedish Medical Center-First Hill
    Registry record
    NCT05174169 · updated
  9. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Swedish Medical Center-Ballard Campus · Swedish Medical Center-Cherry Hill · Swedish Medical Center-First Hill
    Registry record
    NCT05334069 · updated
  10. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Wake Forest University Health Sciences
    Study sites
    Kaiser Permanente Washington · Swedish Medical Center-Ballard Campus · Swedish Medical Center-First Hill
    Registry record
    NCT06418204 · updated
  11. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Fred Hutchinson Cancer Research Center · Swedish Cancer Institute
    Registry record
    NCT06662786 · updated
  12. A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Swedish Cancer Institute
    Registry record
    NCT06663319 · updated
  13. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT06750094 · updated
  14. Family Communications After Genetic Testing

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Swedish Medical Center-Ballard Campus · Swedish Medical Center-Cherry Hill · Swedish Medical Center-First Hill
    Registry record
    NCT07143487 · updated
  15. First-in-human Study of 7MW4911 in GI Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Mabwell (Shanghai) Bioscience Co., Ltd.
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT07216560 · updated
  16. A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    University Of Washington /ID# 271298
    Registry record
    NCT06820463 · updated
  17. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    A2 Biotherapeutics Inc.
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT04981119 · updated
  18. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    Fred Hutchinson Cancer Center / University of Washington
    Registry record
    NCT04657068 · updated
  19. T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Fred Hutchinson Cancer Center
    Study site
    Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT06043713 · updated
  20. A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    University Of Washington /ID# 281451
    Registry record
    NCT07525206 · updated
  21. SMP-3124LP in Adults With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Sumitomo Pharma America, Inc.
    Study site
    University of Washington
    Registry record
    NCT06526819 · updated
  22. A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Criterium, Inc.
    Study site
    Swedish Cancer Institute
    Registry record
    NCT06992258 · updated
  23. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Fred Hutchinson Cancer Research Center
    Registry record
    NCT05786924 · updated
  24. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Fred Hutchinson Cancer Center · Swedish Cancer Institute · Swedish Medical Center
    Registry record
    NCT07222800 · updated
  25. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    University of Washington, Fred Hutchinson Cancer Center
    Registry record
    NCT04585750 · updated
  26. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT06625775 · updated
  27. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT06445062 · updated
  28. Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    OHSU Knight Cancer Institute
    Study site
    Fred Hutch
    Registry record
    NCT05081024 · updated
  29. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Fred Hutchinson Cancer Center
    Registry record
    NCT06253871 · updated
  30. Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Fred Hutchinson Cancer Center
    Study sites
    Benaroya Research Institute at Virginia Mason · Fred Hutch/University of Washington Cancer Consortium
    Registry record
    NCT06995924 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Seattle, WA on ClinicalTrials.gov.

Ask about studies near Seattle

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call